Assessment of diabetic macrovascular complications: A prediabetes model

British Journal of Biomedical Science

Volumn 67, Issue 2, 2010, Pages 59-66

  Nwose, E U ^a,b   Richards, R S ^b   McDonald, S ^b   Jelinek, Herbert F ^b   Kerr, P G ^c   Tinley, P ^b  

^a South West Pathology Service ^*  (Australia)

^b CHARLES STURT UNIVERSITY   (Australia)

^c CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Diabetic vascular complications; Heart diseases; Mass screening; Prediabetic state

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; D DIMER; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; METHEMOGLOBIN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VISCOSITY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ERYTHROCYTE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OXIDATIVE STRESS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VASCULAR DISEASE;

EID: 77954345381     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2010.11730292     Document Type: Article

References (39)

1. Taniyama Y, Griendling KK. Reactive oxygen spedes in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42: 1075-81.
2. Yan S, Ramasamy R, Naka Y, Schmidt A. Glycation, inflammation and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159-69.
3. Caboral M, Mitchell J. New guidelines for heart failure focus on prevention. Nurse Pract 2003; 28: 13, 16, 22-3.
4. Bell DSH. Chronic complications of diabetes. South Med J 2002; 95: 30-4.
5. Vijan S, Stevens DL, Herman WH, Funnell MM, Standiford CJ. Screening, prevention, counselling and treatment for the complications of type II diabetes mellitus: purring evidence into practice. J Gen Intern Med 1997; 12: 567-80.
6. Shaw JE, Chisholm DJ. Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. Med J Aust 2003; 179: 379-83.
7. Tirosh A, Shai I, Tekes-Manova D et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005; 353: 1454-62.
8. Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005; 28: 2472-9.
9. Festa A, Williams K, Hartley AJG et al. Pre-diabetes associated with lipid abnormalities. Circulation 2005; 111: 3465-72.
10. Banerjee M, Cruickshank JK. Prediabetes: is the term useful? Br J Diabetes Vasc Dis 2004; 4: 221-5.
11. Williams DE, Cadwell BL, Cheng YJ et al. Prevalence of impaired fasting glucose and its relationship with cardiovascular disease risk factors in US adolescents, 1999-2000. Pediatrics 2005; 116: 1122-6.
12. Beaser RS, Blonde L, Weissman PN. Metabolic syndrome and cardiovascular risk: treating the clinical spectrum. Medscape 2005 (http://cme.medscape.com/ viewprogram/4685) (Accessed 15 August 2009).
13. Eyre H, Kahn R, Robertson RM. Preventing cancer, cardiovascular disease and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association and the American Heart Association. Circulation 2004; 109: 3244-55.
14. Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 2006; 47: 65-71. (Pubitemid 43005166)
15. Michos ED, Nasir K, Braunstein JB et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis 2006; 84: 201-6.
16. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109: IV6-19.
17. Smith DA. Atherosclerotic cardiovascular disease: emerging laboratory risk factors. Clin Lab Med 2006; 26: ix-xi.
18. New Zealand Guidelines Group 2005. The assessment and management of cardiovascular risk. Handbook for Primary Care Practitioners. (www.nzgg.org.nz/guidelines/0101/050624-CVD-Resource-(Final)-v5-for-printing-2. pdf) (Accessed 15th August 2009).
19. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-25.
20. Vijayalingam S, Parthiban A, Shanmugasundaram KR, Mohan V. Abnormal antioxidant status in impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabet Med 2004; 13: 715-9.
21. Kacmaz M, Ozturk HS, Cete S, Kavutcu M, Durak I. The effects of smoking on antioxidant defence system and membrane free fatty acid content of erythrocytes and plasma lipid parameters: protective role of antioxidant vitamins. Nutr Res 1997; 17: 931-40.
22. American Diabetes Association. Pre-diabetes. (www.diabetes.org/diabetes- prevention/pre-diabetes.jsp). (Accessed 15 August 2009).
23. American Diabetes Association. Frequently asked questions about pre-diabetes. (www.diabetes.org/pre-diabetes/faq.jsp). (Accessed 15 August 2009).
24. Nwose EU, Jelinek HF, Richards RS, Kerr PG. Erythrocyte oxidative stress in clinical management of diabetes and its cardiovascular complications Br J Biomed Sci 2007; 64: 35-43. (Pubitemid 46952971)
25. Dominguez C, Ruiz E, Gussinye M, Carrascosa A. Oxidative stress at onset and in early stages of type I diabetes in children and adolescents. Diabetes Care 1998; 21: 1736-42.
26. Goldfarb AH, Bloomer RJ, McKenzie MJ. Combined antioxidant treatment effects on blood oxidative stress after eccentric exercise. Med Sci Sports Exerc 2005; 37: 234-9.
27. Manuel y Keenoy B, Vertommen J, De Leeuw I. Divergent effects of different oxidants on glutathione homeostasis and protein damage in erythrocytes from diabetic patients: effects of high glucose. Mol Cell Biochem 2001; 225: 59-73.
28. Memisogullari R, Taysi S, Bakan E, Capoglu I. Antioxidant status and lipid peroxidation in type II diabetes mellitus. Cell Biochem Funct 2003; 21: 291-6.
29. Tsimikas S. Measures of oxidative stress. In: Smith DA ed. Atherosclerotic cardiovascular disease: emerging laboratory risk factors. Clin Lab Med 2006; 26: 571-90.
30. Malone PC, Agutter PS. The aetiology of deep venous thrombosis. QJM 2006; 99: 581-93.
31. Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol 2008; 143: 180-90.
32. Nwose EU, Richards RS, Kerr PG, Tinley P, Jelinek HF. Atherothrombosis and oxidative stress: the connection and correlation in diabetes. Redox Rep 2009; 14: 55-60.
33. Nwose EU, Richards RS, Kerr RG, Tinley R, Jelinek H. Oxidative damage indices for the assessment of subclinical diabetic macrovascular complications. Br J Biomed Sci 2008; 65: 136-41.
34. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR; Australian Diabetes Society; Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 2007; 186: 461-5.
35. Linder R, Konig IR, Weimar C, Diener HC, Poppl SJ, Ziegler A. Two models for outcome prediction: a comparison of logistic regression and neural networks. Methods Inf Med 2006; 45: 536-40.
36. Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-478.
37. Ziegler D, Sohr CGH, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004; 27: 2178-83.
38. Smith GD, Timpson N, Lawlor DA. C-reactive protein and cardiovascular disease risk: still an unknown quantity? Ann Intern Med 2006; 145: 70-2.
39. Kemp TM, Barr EL, Zimmet PZ et al. Glucose, lipid and blood pressure control in Australian adults with type 2 diabetes: the 1999-2000 AusDiab. Diabetes Care 2005; 28: 1490-2.